Psoriasis Therapeutics in Asia-Pacific Markets to 2021 Advent of Novel Biologics and Expanding Treatment Pool to Drive Growth - Worldwide Industry Size, Share, Trend, Analysis, Research Report

Psoriasis Therapeutics in Asia-Pacific Markets to 2021 Advent of Novel Biologics and Expanding Treatment Pool to Drive Growth - Worldwide Industry Size, Share, Trend, Analysis, Research Report

Research, the leading business intelligence provider, has released its latest research, ""Psoriasis Therapeutics in Asia-Pacific Markets to 2021: Advent of Novel Biologics and Expanding Treatment Pool to Drive Growth"", which provides insights into psoriasis therapeutics in the Asia-Pacific (APAC) market. For the purposes of this report, APAC refers to the market in China, India, Japan, and Australia only. The report estimates the market size for 2014, along with forecasts until 2021.

To Browse a Full Report with TOC: http://www.researchmoz.us/psoriasis-therapeutics-in-asia-pacific-markets-to-2021-advent-of-novel-biologics-and-expanding-treatment-pool-to-drive-growth-report.html

It also covers disease epidemiology, treatment algorithms, treatment use patterns, in-depth analysis of pipeline molecules, clinical trial failure rates, and analysis of recent deals. It is built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis carried out by GBI Research’s team of industry experts.

In 2014, the value of the psoriasis therapeutics market in APAC amounted to an estimated $690m, and it is forecast to grow at a Compound Annual Growth Rate (CAGR) of 8.4% between 2014 and 2021 to reach $1.2 billion. The psoriasis treatment landscape is a particularly complex one. More than 80% of patients fall into the mild-or-moderate category, for which the first line of treatment is topical drugs, phototherapy, or a combination. In the case of severe patients, non-steroidal drugs such as methotrexate, cyclosporine, and acitretin are practiced as first-line treatment; however, they come with toxicity concerns and so cannot be prescribed for long durations. Biologics such as TNF inhibitors (adalimumab, etanercept, infliximab) and ustekinumab are largely prescribed as second-line therapy when none of the aforementioned options provide the desired results.

To Download Sample Report With TOC:...

Similar Essays